|
| Way of secretion | Molecule | Functional role in cardiovascular repair | References |
|
| Direct secretion | Adrenomedullin | Angiogenic and cardioprotective factor | [13] |
| Angiogenin | LV remodeling attenuation through vasculogenesis | [31] |
| Basic fibroblast growth factor (bFGF, FGF-2) | Vascular regeneration and attenuation of apoptotic pathways, leading to reduced remodeling | [32] |
| CXCL12 | Endothelial tube formation | [33] |
| Cystatin C | Fibroblast chemoattraction | [34] |
| Cysteine-rich angiogenic inducer (Cyr61) | Angiogenesis promotion | [35] |
| Dickkopf-related proteins (Dkk) | JNK signaling activation, eventually resulting in cardiomyogenesis | [36] |
| ECM structural proteins | Fibroblast chemoattraction | [34] |
| Hepatocyte growth factor (HGF) | Mobilization of cardiac progenitor cells | [13] |
| Hypoxic induced Akt regulated stem cell factor (HASF) | Cardiomyocytes survival improvement | [37] |
| Insulin-like growth factor (IGF) | Antiapoptotic effect, angiogenesis promotion, and activation of resident CSCs | [38] |
| Interleukin-1 (IL-1) | Angiogenesis promotion | [39] |
| Interleukin-6 (IL-6) | VEGF induction | [13, 39] |
| Leukemia inhibitory factor (LIF) | Mobilization of BM-progenitor cells and cardioprotection promotion | [40] |
| Pigment epithelium-derived factor (PEDF) | Fibroblast chemoattraction | [34] |
| Placental growth factor (PLGF) | Prevention of cell death of cardiomyocytes and endothelial cells | [13] |
| Secreted Frizzled Related Protein (SFRP 2) | Fibrosis and apoptosis reduction, promotion of MSC self-renewal and engraftment | [41, 42] |
| Soluble TNFR1 (sTNFR1) | Inflammatory response attenuation | [43] |
| Stem cell-derived factor (SDF-1) | Stem cell recruitment and cardiomyocyte and MSC survival | [32, 44] |
| TNF-α stimulated gene-6 (TSG-6) | Anti-inflammation action | [17] |
| Vascular endothelial growth factor (VEGF) | Prevention of cell death of cardiomyocytes and endothelial cells | [13] |
|
| Exosomes | miR-19a | Akt/ERK signaling activation, through PTEN targeting | [45] |
| miR22 | Apoptosis reduction and ischemic CMCs injury improvement, through Mecp2 targeting | [46] |
| 20S proteasome subunits (PMSA 1-7) | Cardioprotection through proteolytic degradation of misfolded proteins | [47] |
| Unknown | PMEC migration and vascularization improvement | [48] |
| Unknown | Angiogenesis promotion | [49] |
| Unknown | VEGF level incensement and angiogenesis promotion | [50] |
| Unknown | Oxidative stress inhibition, PI3K/Akt pathway activation and inflammatory activity reduction | [51] |
| Unknown | Hypoxic signal pathway inhibition | [52] |
|
| Microvesicles | miR221 | CMCs apoptosis reduction and CMCs survival improvement | [53] |
| Unknown | Endothelial cell proliferation and blood flow recovery | [54] |
|